Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH

Medicine Matters oncology

Thyroid dysfunction is the second most frequent endocrine organ involved in ICI therapy although, unfortunately, data gathered from clinical trials is limited. Damage to the thyroid gland induced by ICI agents can present as thyroiditis, hypothyroidism, or transient hyperthyroidism. Rare cases of Graves' ophthalmopathy have also been reported, with patients reporting periorbital or pain in the extraocular muscles, with lab tests showing elevation of thyroid stimulating hormone (TSH)-receptor antibodies but normal thyroid function [1].